Eurand to Present at UBS Global Specialty Pharmaceuticals Conference
in London
PHILADELPHIA, PA--(Marketwire - May 20, 2009) - Eurand N.V. (NASDAQ:
EURX), a specialty pharmaceutical company that develops enhanced
pharmaceutical and biopharmaceutical products based on its
proprietary pharmaceutical technologies, announced today that Gearóid
Faherty, Chairman and Chief Executive Officer, is scheduled to
present at the following conference:
Event: UBS Global Specialty Pharmaceuticals Conference
Date: Tuesday, June 2, 2009
Time: 11:00 a.m. BST (6:00 a.m. ET)
Location: The Waldorf Hilton Hotel
London, U.K.
An audio webcast of the Company's presentation will be available by
accessing the investor relations section of Eurand's web site at
www.eurand.com and will be available via replay until July 2, 2009.
About Eurand
Eurand is a specialty pharmaceutical company that develops,
manufactures and commercializes enhanced pharmaceutical and
biopharmaceutical products based on its proprietary pharmaceutical
technologies. Eurand has had five products approved by the FDA since
2001 and has a pipeline of product candidates in development for
itself and its collaboration partners. The Company's technology
platforms include bioavailability enhancement of poorly soluble
drugs, custom release profiles, taste-masking orally disintegrating
tablet (ODT) formulations, and drug conjugation.
Eurand is a global company with facilities in the U.S. and Europe.
For more information, visit www.eurand.com.
Contacts:
Bill Newbould
Vice President, Investor Relations
Eurand N.V.
+1 267-759-9335
bill.newbould@eurand.com
Nick Laudico/Sara Pellegrino
The Ruth Group
+1 646-536-7030/7002
nlaudico@theruthgroup.com
spellegrino@theruthgroup.com
This announcement was originally distributed by Hugin. The issuer is
solely responsible for the content of this announcement.
